Latest Breaking News On - Vista strategies - Page 1 : comparemela.com

HighVista Strategies Closes Oversubscribed Private Equity Fund X

HighVista Strategies Closes Oversubscribed Private Equity Fund X
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United statesJohn dickieScott reedHighvista strategies closes oversubscribed private equity fundHighvista strategiesVista strategiesNorth star

Enliven Therapeutics (NASDAQ:ELVN) Stock Price Down 3 9% After Insider Selling

Enliven Therapeutics (NASDAQ:ELVN) Stock Price Down 3 9% After Insider Selling
themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.

Samuel kintzManish patelEnliven therapeutics incChina universal asset management coSg americas securitiesExchange traded conceptsManufacturers life insurance companyEnliven therapeutics company profileSecurities exchange commissionHighvista strategiesEnliven therapeuticsGet free reportExchange commissionUniversal asset managementTraded conceptsVista strategies

Aerovate Therapeutics (NASDAQ:AVTE) Trading Down 3 9%

Aerovate Therapeutics (NASDAQ:AVTE) Trading Down 3 9%
theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.

Switzerland generalUnited statesHunter gilliesRalph nivenSilverarc capital managementWells fargo companyHighvista strategiesAerovate therapeutics incSwiss national bankCrossover managementAlps advisors incJefferies financial groupAerovate therapeuticsGet free reportFinancial groupNational bank

Jefferies Financial Group Begins Coverage on Aerovate Therapeutics (NASDAQ:AVTE)

Jefferies Financial Group started coverage on shares of Aerovate Therapeutics (NASDAQ:AVTE – Free Report) in a research note issued to investors on Monday morning, Marketbeat.com reports. The firm issued a buy rating and a $65.00 price target on the stock. Separately, Wells Fargo & Company initiated coverage on shares of Aerovate Therapeutics in a research […]

United statesSwitzerland generalMarinus verwijsRalph nivenAlps advisors incSilverarc capital managementAerovate therapeutics incHighvista strategiesSwiss national bankDriehaus capital managementAerovate therapeutics company profileSecurities exchange commissionJefferies financial groupWells fargo companyAerovate therapeuticsFree report

Ambrx Biopharma Inc (NYSE:AMAM) Receives $24 13 Consensus Price Target from Brokerages

Ambrx Biopharma Inc (NYSE:AMAM) Receives $24 13 Consensus Price Target from Brokerages
theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.

Ambrx biopharmaRobertw bairdCantor fitzgeraldHighvista strategiesAmbrx biopharma incRoyal bankSilverarc capital managementAmbrx biopharma company profileTd asset management incGet free reportMarketbeat ratingsBiopharma stock downManagement incPoint capital managementVista strategiesAsset management